GoodRx Holdings' third-quarter report comes at a key point in its ongoing shift. The company is moving away from its traditional prescription-transaction model toward higher-margin areas like manufacturer-sponsored Pharma Direct pricing and consumer subscriptions. In the second quarter, Pharma Direct revenue rose 76% year over year to $61.6 million, while subscription revenue increased 39% to $28.5 million, even as prescription-transaction revenue dropped 26% and Monthly Active Consumers fell 12% to 5.0 million. This upcoming report will indicate whether that transition is gaining enough ground to counter pressure on the core business and support the raised full-year guidance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analysts expect GoodRx Holdings to report third-quarter 2026 earnings of approximately $0.08 per share, with consensus revenue estimates clustered near $202 million. That compares with earnings of $0.08 per share on revenue of $196.0 million in the third quarter of 2025. Expectations were reset higher after the company's second-quarter print, when revenue of $200.4 million beat consensus and management lifted full-year 2026 guidance to $790 million to $805 million in revenue and $240 million to $250 million in adjusted EBITDA. Investors will be watching whether Pharma Direct and subscription momentum persists, how quickly prescription-transaction revenue moderates, and whether adjusted EBITDA margins hold up as the company invests in new product launches such as GoodRx Companion and Employer Direct.
Sentiment heading into the report is cautiously optimistic, reflecting management's upgraded guidance and the momentum in Pharma Direct and subscriptions. Following the second-quarter release in August, shares moved higher as the revenue beat and raised outlook reinforced confidence in the strategic pivot. Still, lingering concerns remain: prescription-transaction revenue continues to contract, Monthly Active Consumers are shrinking, and near-term unit economics are under pressure from higher fulfillment and delivery costs tied to newer revenue lines. Investors will be weighing whether the growth engines can scale quickly enough to deliver the guided return to top-line growth, with any disappointment in margin performance or user trends a key risk to the stock's reaction. From what I see, this is important because the pace of the mix shift will likely determine near-term performance.
Beyond the headline numbers, investors should watch several forward-looking signals. The first is the trajectory of Pharma Direct, which management expects to grow more than 70% year over year for 2026. Continued execution here would validate the company's shift toward manufacturer-sponsored pricing, including demand tied to weight-loss and GLP-1 access programs.
Second, subscription growth and the adoption of newer offerings such as GoodRx Companion and the Employer Direct platform will be important. These products carry more durable, recurring economics, but their ramp-up carries incremental costs that could pressure margins in the near term.
Finally, monitor prescription-transaction revenue and Monthly Active Consumers for signs of stabilization. Retail pharmacy disruptions and evolving federal initiatives have weighed on these legacy metrics, and any evidence of a floor would strengthen confidence in the company's ability to hit its full-year revenue and adjusted EBITDA targets. Cost discipline, margin trends, and any commentary on upcoming go-lives across employer and manufacturer partnerships round out the key watch list. I’m watching this closely as the results unfold.
In preparing for earnings season, I often turn to Tickeron’s AI Screener to quickly filter stocks by industry trends, technical patterns, and fundamentals. It helps me spot comparable names and refine my watchlist without spending hours on manual screens, which is especially useful when evaluating names like GDRX ahead of key reports. The tool’s customizable filters make it straightforward to compare revenue growth trajectories and margin profiles across peers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Stochastic Oscillator for GDRX moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 46 of the 56 cases the stock moved lower. This puts the odds of a downward move at 82%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GDRX as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for GDRX turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 35 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
GDRX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
GDRX moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GDRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +4.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDRX advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 124 of 147 cases where GDRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. GDRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.849) is normal, around the industry mean (4.523). GDRX has a moderately high P/E Ratio (58.500) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.494) is also within normal values, averaging (6.105).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ServicestotheHealthIndustry